Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
– Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose […]